Global CMC support for US biotech sponsors

For US biotech companies, CMC rarely stays inside one country. Even programmes

that start with a single CDMO often end up split across regions: process

development in one place, GMP manufacture somewhere else, and analytical testing

handled by a specialist lab with its own timelines and constraints. Sometimes that’s

deliberate. Often, it happens because a vendor can’t take you into the next phase, a

slot disappears, or you need to manufacture closer to the clinic.

Core technical work follows well-understood scientific principles, but moving from lab

discovery to GMP manufacturing is rarely a straight transfer. With biologics, the

process is the product. Small changes in cell culture conditions or scale can shift

quality attributes such as glycosylation or aggregation, sometimes without warning.

Problems tend to surface when this technical sensitivity collides with poor

coordination between sites, where decisions are made in isolation and changes

ripple through the programme unchecked.

A common pattern looks like this: you choose a CDMO that can move quickly,

generate early data, and help you build momentum. Then the next stage arrives —

tech transfer, scale-up, release testing, stability — and the programme becomes a

coordination problem. The analytical method package doesn’t translate cleanly to the

new site. Specifications need to be revisited. A “small” process change creates a

comparability question. A batch is ready, but the release plan isn’t as clear as it

needs to be. You lose time simply because the programme wasn’t set up to handle

change without rework.

This is exactly where an external CMC team can help: keeping the programme

joined up as sites, methods and timelines start shifting. It’s also often the point where

many sponsors start thinking globally, whether they intended to or not.

3Biotech supports US-based sponsors running development across the US and

Europe. We handle the practical work needed for clinical batch release, including

batch record review and deviation handling, so your US Quality Unit can complete

batch disposition. At the same time, we manage the Qualified Person certification

required for European clinical trials. This keeps your CMC activities consistent and

compliant on both sides of the Atlantic, without gaps between regulatory

expectations.

Why CMC complexity doesn’t stop at borders

As development progresses, CMC work becomes less about individual tasks and

more about coordination. Even a lean early-stage programme has process

development, analytical strategy, quality oversight, and clinical supply planning

moving forward in parallel.

Once activities are distributed across sites and regions, the issues tend to appear in

the joins. A method that worked well in development may not be ready for GMP

release. A specification that seemed reasonable early on may become difficult to

justify after scale-up. A manufacturing site change triggers comparability questions,

and suddenly the programme needs to defend consistency across material sets that

weren’t originally designed to be compared.

Global development can work extremely well, but only when it’s treated as one

connected system rather than a series of hand-offs.

How global CMC programmes stay on track

It’s no great secret that most CMC delays aren’t caused by one major technical

failure. They come from smaller disconnects that compound: incomplete tech

transfer packages, unclear responsibilities between sponsor and CDMO, late

changes to analytical scope, or control strategies that are tightened abruptly right

before a milestone.

The strongest programmes usually share one thing in common: they’re built to

absorb change. That might be a shift in batch size, a change in manufacturing site,

an updated impurity profile, or a method that needs refinement to meet release

timelines. When the programme has been designed to manage those changes,

teams spend less time backtracking and more time progressing.

Getting CDMO selection right the first time

CDMO selection is rarely a single decision. It’s a chain of decisions made under time

pressure, with limited data, and evolving priorities as the programme matures.

A partner may be suitable for feasibility and early process work, but not for clinical

manufacture. A site can look strong in a capability deck, then struggle once the

process details are understood. And even when the technical fit is there, capacity

and scheduling can shift quickly. That’s why structured CDMO selection and

oversight tends to pay for itself, especially when timelines are tight.

What helps is being clear about what “fit” really means for the next stage. That

includes platform experience, batch size range, analytical capabilities, availability of

single-use or containment where needed, and a realistic plan for release testing and

batch disposition. It also means understanding early whether a site can support both

current clinical needs and near-term progression, rather than forcing a switch

midstream.

Avoiding EU–US misalignment as the programme progresses

Transatlantic development rarely fails because FDA and EMA expectations are

fundamentally different. It fails because the programme was built around one region,

and then has to be reshaped quickly to fit another.

Small differences in how specifications are justified, how release testing is

structured, or when method validation is introduced can create delays later,

particularly when clinical release timelines tighten or a submission is approaching.

The fix is making sure key decisions hold up across regions, and that the CMC

narrative remains consistent even when work moves between vendors. It’s much

easier to maintain that consistency when som.eone maintains a consistent CMC

narrative as the programme evolves.

A frequent hurdle for US sponsors is the transition from the US 'Quality Unit' model

to the European 'Qualified Person' (QP) requirement. In the EU, the QP bears

personal legal liability for certifying that each batch complies with the Clinical Trial

Application (CTA) and GMP standards. Without an EU-based QP declaration and the

necessary site audits of US manufacturing facilities, importation into the clinic can

face massive delays. 3Biotech acts as your local expert to navigate these personal

liability requirements and streamline the certification process.

Keeping cross-border manufacturing practical, not complicated

Many sponsors prefer to keep manufacturing and testing within one region, but CMC

doesn’t always allow that for long.

As programmes move forward, teams often need additional options due to capacity

constraints, capability gaps, or commercial pressures. That can be a sensible step,

but every new site or supplier adds more interfaces, more transfers, and more

opportunities for inconsistency unless the technical package stays tightly managed.

The programmes that run smoothly tend to treat cross-border manufacturing as part

of the strategy, not a last-minute workaround. That means anticipating change

points, maintaining comparability logic, and keeping analytical and quality

approaches aligned even as delivery shifts.

Building a phase-appropriate CMC strategy that holds up later

Early-stage CMC doesn’t need to look like a commercial programme, but it does

need to be controlled enough to deliver safe and compliant clinical supply. The most

common issue is that early decisions don’t always carry forward cleanly. Methods

evolve, processes shift, sites change, and choices that felt settled suddenly need

rewriting under pressure.

A phase-appropriate strategy reduces that risk by being clear on what needs to be

true now, while leaving room for development to progress without constant resets.

That includes analytical methods that support release timelines, specifications that

can be justified, and tech transfer packages that enable execution rather than just

documentation.

Staying phase-appropriate also means leveraging the latest regulatory evolutions,

such as the FDA’s 2026 'flexible approach' for Cell and Gene Therapies (CGT). For

programs targeting rare diseases, navigating the 'New Plausible Mechanism

Pathway' allows for greater flexibility in commercial specifications and process

validation. 3Biotech ensures your CMC narrative is robust enough to meet traditional

standards while remaining agile enough to take advantage of these new regulatory

tailwinds for accelerated approval.

Managing cost without weakening the technical approach

For emerging and mid-stage biotech teams, cost control is part of keeping the

programme alive.

The challenge is that cost-cutting in CMC rarely shows up immediately. It tends to

appear later as repeat work, delayed batches, or rushed fixes ahead of a milestone.

The most sustainable approach is usually to keep the programme lean, where it can

be lean, and invest where it genuinely reduces risk: vendor fit, transfer readiness,

analytical suitability for release, and clarity on what the next milestone will require.

What this looks like in practice for US biotech teams

When global CMC is working well, it feels almost uneventful. Tech transfer doesn’t

become a fire drill. Release testing and batch disposition are planned rather than

improvised. Site changes don’t trigger large-scale rework. The programme stays

coherent even when delivery is spread across vendors.

Most importantly, decisions around manufacturing, analytical strategy, and clinical

supply remain aligned, even as the programme expands across regions.

CMC strategy doesn’t stay regional for long. Most programmes become global by

necessity.

Strengthen your global CMC pathway with 3Biotech

If you’re a US biotech sponsor managing development across the US and Europe —

or preparing for that shift — 3Biotech can support you with CDMO selection and

oversight, tech transfer readiness, and a CMC strategy that stays coherent as your

programme evolves.

Get in touch to explore how we can help you reduce rework, protect timelines

and keep clinical supply moving.

Contact us